Wrist access may ease liver cancer treatment
NCT ID NCT07160374
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new way to deliver chemo directly to liver tumors using a wrist artery instead of the groin. Thirty-eight patients with liver cancer took part. The goal was to see if the wrist approach is safe, feasible, and effective, with fewer complications and faster recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HepaSphere drug-eluting microspheres
- What this could lead to
- If successful, this approach could make TACE safer and more comfortable for liver cancer patients, with faster recovery.
- What could go wrong
- This is a small, single-center study with only 38 participants. Results may not apply to all patients, and the procedure still carries risks like bleeding or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
Seoul, Songpa-gu, 05505, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?